Psychometric properties of patient reported outcome measures in idiopathic pulmonary fibrosis

Jee Whang Kim1, Allan Clark1, Surinder S Birring2, Christopher Atkins1, Moira Whyte3 and Andrew M Wilson1

Abstract
Background: Various patient reported outcome measures (PROMs) are used in idiopathic pulmonary fibrosis (IPF). We aimed to describe their psychometric properties, assess their relationship with 1-year mortality and determine their minimal clinically important differences (MCIDs). Methods: In a prospective multicentre study, participants with IPF completed the King’s Brief Interstitial Lung Disease Questionnaire (K-BILD), the modified Medical Research Council (mMRC) dyspnoea scale, St George’s Respiratory Questionnaire (SGRQ) and University of California, San Diego shortness of breath questionnaire (UCSD-SOBQ) three-monthly intervals over a 12-month period. Forced vital capacity (FVC) was matched with questionnaires and mortality was captured. Anchor- and distribution-based methods were used to derive MCID. Results: Data were available from 238 participants. All PROMs had good internal consistency and high degree of correlations with other tools (except UCSD-SOBQ correlated poorly with FVC). There were significant associations with mortality for K-BILD (hazard ratio 16.67; 95% CI 2.38–100) and SGRQ (hazard ratio 4.65; 95% CI 1.32–16.62) but not with the other PROMs or FVC. The median MCID (range) for K-BILD was 6.3 (4.1–7.0), SGRQ was 7.0 (3.8–9.6), mMRC was 0.4 (0.1–0.5) and UCSD-SOBQ was 9.6 (4.1–14.2). Conclusions: The K-BILD was related to other severity measures and had the strongest relationship with mortality.

Keywords
Patient reported outcome measures, idiopathic lung disease, minimal clinically important difference, mortality

Introduction
Idiopathic pulmonary fibrosis (IPF) is a chronic progressive fibrotic lung disease with significant morbidity and mortality.1 Assessing patient reported outcome measures (PROMs), including assessments of breathlessness and health-related quality of life (HRQOL), in people with IPF is important as they are outcomes of clinical trials2 and part of clinical service specifications (www.nice.org.uk/CG163). However, as no universally accepted tool exists, different patient PROMs used.

The St George’s Respiratory Questionnaire (SGRQ)3 and King’s Brief Interstitial Lung Disease Questionnaire (K-BILD)4 are the most commonly employed tools in IPF. However, the SGRQ was developed for use in people with chronic obstructive pulmonary disease (COPD), for which its minimal important clinical difference (MCID) is between
7 and 10, and although it relates to physiological impairment in IPF, an IPF-specific version (SGRQ-I) has been developed and validated. In terms of assessing breathlessness in IPF, the University of California, San Diego shortness of breath questionnaire (UCSD-SOBQ) and the modified Medical Research Council (mMRC) dyspnoea scale are the most frequently used, both of which were also developed mostly in patients with COPD. The EuroQol five dimension five level (EQ-5D-5L) is a well-validated global health status instrument designed for use in clinical and health-economic trials. Anxiety and depression are common in IPF and related to HRQOL; it can be assessed by the Hospital Anxiety and Depression Score (HADS).

Assessment of the psychometric properties of PROMs in people with IPF is important to understand their suitability for use in clinical research and practice. The psychometric properties of SGRQ in people with IPF have been reviewed and recently evaluated from data of trials of nintedanib. Likewise, the validation of K-BILD and SGRQ-I has also been evaluated separately in a Danish cohort of 150 people with IPF. However, neither the HADS nor the mMRC have been validated in IPF. Our aim, in this large prospective multicentre UK-wide study, was to describe the internal consistency, construct validity and known group validity of the SGRQ, K-BILD, mMRC dyspnoea score, UCSD-SOBQ, HADS and EQ-5D-5L simultaneously so that their qualities can be contrasted. We aimed to determine their MCID and relationship to 1-year mortality.

Methods

This was an observational prospective longitudinal multicentre study, of seven specialist interstitial lung disease (ILD) centres throughout the UK (Bristol, Cambridge, Devon & Exeter, Newcastle, North Staffordshire, Norwich and Sheffield) over 12 months. Participants were identified by clinical staff and recruited by local researchers who administered the questionnaires. The questionnaires were self-completed unsupervised either in hospital reception rooms or at home. Data were collected between July 2014 and October 2016. The study was conducted according to the principles of Good Clinical Practice. It was approved by NRES Committee South West–Exeter (Reference number 14/SW/0047) and registered on the clinicaltrials.gov database (Identifier NCT02176707).

Participants

Participants were identified by reviewing hospital databases, patient registries and medical notes. Participants were eligible for enrolment if they were aged more than 40 years and had IPF based on multidisciplinary consensus, according to contemporaneous guidelines, and were able to provide written informed consent. Participants were excluded if they had a significant co-existing respiratory disease, medical or psychiatric condition exhibiting a clinically relevant effect on symptoms, HRQOL and disease progression as determined by the principal investigator. Participants with airflow obstruction defined as a ratio of forced expiratory volume in 1 s (FEV1) to forced vital volume (FVC) of less than 0.6 or a residual volume greater than 120% predicted were also excluded.

Outcome measures

The following PROMs were presented in the order below, but the order of completion was not monitored. EQ-5D-5L contains five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension is answered on a five-level scale (1 no problems, five severe problems/unable to do). It was converted to utilities using standard UK health state valuations. K-BILD describes health status during the past 2 weeks in people with ILD. It contains 15 questions evaluating three dimensions: psychological, breathlessness and activity, and chest symptoms on a seven-point Likert scale. Total score ranges from 0 (worst health status) to 100 (best health status). SGRQ incorporates 50 items across three domains: symptoms, activity and impacts. The total score ranges from 0 (best health status) to 100 (worst health status). The SGRQ-I was generated from the SGRQ data. The mMRC is commonly used to assess breathlessness, and response is classified into the five-point scale (0 dyspnoea with strenuous exercise, four too breathless to leave house or breathless when dressing). The UCSD-SOBQ is a domain-specific tool assessing breathlessness associated with activities of daily living. It includes 24 questions, rating answers on a 0 (not at all breathless) to 5 (maximally breathless) point scale. The total scores range from 0 (lesser dyspnoea) to 120 (greater dyspnoea). HADS contains seven questions for anxiety and seven questions for depression. Scores can be added to measure psychological distress. Patient Global Impression of Change (PGIC) is used to quantify perceived changes in health status over time scale. We used a 15-point scale in this study.

Spirometry and a six-minute walk test (6MWT) were performed unless undertaken for clinical reasons within the preceding 4 weeks. Additional physiological data were obtained from the medical notes, including static lung volumes and total lung diffusing capacity of carbon monoxide (DLCO), if these had been conducted as part of routine care within 4 weeks of questionnaire completion. The visit schedule was aligned to routine care with follow-up measurements (PROMs and spirometry) collected approximately every 3 months. Participants unable or unwilling to attend for clinic visits were mailed the questionnaires after ensuring their vital status.
were matched if they were completed within 14 days of each other. They were also matched with physiological data if they were within 28 days of each other. Questionnaires with no reliable date were not included in the analysis. Mortality data were obtained from serious adverse event logs. Deaths were verified by the principal investigator at each site, and vital status was checked prior to mailing PROMs but was not cross referenced to Office of National Statistics (ONS) data.

Data from all PROMs were captured even if the return date was not at 3-monthly intervals. All PROMs were electronically scanned using formic optical character recognition software (Formic Limited, Middlesex, Uxbridge, UK) and scored by the research team and analysed by the study statistician (AC).

**Statistical analysis**

A sample size of 200 has 99% power to detect a correlation of 0.3 at 5% significance for the convergent validity analysis, and a sample size of 150 provides 86% power to detect a difference of 0.5 of a standard deviation between the groups for the known groups analysis.

**Internal consistency**

Internal consistency was assessed using the Cronbach’s α coefficient at baseline, and the confidence interval was estimated based on a bootstrap with 500 replications. We considered a value greater than 0.7 to represent a homogenous scale.

**Convergent validity**

Convergent validity was evaluated by assessing the correlation between the different HQROL and breathlessness tools and physiological measurements including FVC % predicted and 6-min walk distance (6MWD) using Spearman correlation coefficients. Correlations were considered as weak if <0.30, moderate, 0.3–0.6 and strong >0.60. We hypothesised that the correlation between K-BILD and SGRQ would be strong\(^4\) and between K-BILD and FVC would be weak.\(^5\) We expected there to be inverse relationships between PROMs with opposite directions and that low FVC related positively to poor health states identified by the PROMs.

**Known-group validity**

Known group validity was assessed by measuring the difference between the values, using a two sample t-test, for the first measurement obtained from people with FVC >75% and values from people with FVC ≤75%, that is, only one measurement was obtained for each person.\(^24\)

**Relationship with 1-year mortality**

The Kaplan–Meier curve was used to describe the survival time. A tertile analysis was undertaken to describe relationship between 1-year mortality and each PROM tool. Individuals were divided into three equal groups according to the baseline total score of each questionnaire: group 1 (better health status), group 2 and group 3 (worse health status). A comparison of survival between tertile groups was made. Cox’s proportional hazards model was used to estimate the hazard ratio for each variable separately with no adjustment for potential confounding factors. Analysis was repeated using FVC % predicted. Patients were divided into two groups based on lung function (FVC> 75% or FVC ≤75%).

**Minimal clinically important difference**

Anchor-based method was used to derive MCID of the PROMs.\(^25\) To detect MCID within patients (longitudinal), patients were stratified into two groups based on difference in PGIC from the first visit to the second visit.\(^26\) Data were restricted to those patients with visits less than 100 days apart. Participants were considered as unchanged if (−1, 0, 1) and minimally changed if (−2 and −3). Distribution-based methods were also used to derive estimates of the MCID. The standard error of measurement (SEM) method was used. The intraclass correlation coefficient for this method was estimated using data from participants who reported that their health did not change between visits. The 0.5 × SD method was also used based on the SD of the measurement at the start of the study.

**Results**

**Participants**

Two hundred and fifty participants were enrolled into this study, and data were available from 238 individuals (Table 1). The median time between visits was 98 days (ranged from 16 to 447 days). There were a total of 778 evaluable EQ-5D-5L questionnaires with each individual having an average of 3.3 questionnaires. There was greater variation between individuals than within individuals for change over 12 months, that is, participants’ outcome measures were relatively static over the 12-month period (Table 2). There was a large amount of missing data (15% at second visit (Table 2)) because of patient withdrawal.

**Internal consistency**

All questionnaires showed good internal consistency with Cronbach’s alpha coefficients of >0.8. The Cronbach’s alpha and 95% CI were EQ-5D: 0.86 (0.84, 0.87), HADS:
Convergent validity
The correlations between questionnaires were mostly strong (Table 3). The mMRC dyspnoea scale showed moderate correlations with FVC % predicted and 6MWD. SGRQ, SGRQ-I and K-BILD had a moderate correlation with FVC % predicted but a weak correlation with 6MWD. Correlation between UCSD-SOBQ and 6MWD was moderate, but correlation between UCSD-SOBQ and FVC % predicted was weak. EQ-5D and HADS showed weak correlations with both FVC % and 6MWD (Table 3).

Known-group validity
People with FVC % predicted ≤75% had higher mean SGRQ, mMRC and UCSD-SOBQ scores and lower mean EQ-5D and K-BILD scores. There was no statistically significant difference in mean HADS scores between the groups (Table 4).

Relationship to 1-year mortality
There were a total of 26 (10.9%) deaths. The correlation between PGIC and PROMs was weak (r= 0.05 – 0.37). K-BILD showed a strong association with 1-year mortality. People with worse health status (in the lower tertile) had significantly increased risk of deaths than those with best health status (upper tertile) for K-BILD (HR 16.67; 95% CI 2.38 – 100), SGRQ (HR 4.65; 95% CI 1.32-16.62), EQ-5D-5 L (HR 3.70; 95% CI 1.23 – 11.11) but not for mMRC (HR 1.72; 95% CI 0.58 – 5.12), HADS (HR 3.11; 95% CI 0.82 – 11.71), UCSD-SOBQ (HR 1.78; 95% CI 0.58 – 5.43) or SGRQ-I (HR 3.19; 95% CI 1.03 – 9.89) (Figure 1). There was no difference between the survival of those with an FVC higher or lower/equal to 75% predicted (HR 1.67; 95% CI 0.68 – 4.1).

Minimal important clinical difference
Eighty-seven participants were considered unchanged from visit 1 to visit 2, and 36 participants were considered changed minimally. The estimated MCIDs are shown in Table 5.

Discussion
Summary of main findings
This is the first study to report the psychometric properties, MCID and relationship with mortality of seven commonly

---

Table 1. Characteristics of participants (n = 238).

| Characteristic         | N (%) | Mean (SD) |
|------------------------|-------|-----------|
| Male sex               | 171 (71.8) |           |
| Age, years             | 231 | 72.6 (7.6) |
| BMI, kg/m²             | 207 | 27.7 (4.0) |
| Caucasian              | 205 (98.1) |           |
| Disease duration, years| 194 | 3.19 (2.8) |
| Smoking status         | 211 |           |
| Never                  | 52 (26.5) |           |
| Former                 | 150 (71.1) |           |
| Current                | 9 (4.3)   |           |
| HRCT                   |       |           |
| Honeycombing           | 111 (46.6) |           |
| Traction bronchiectasis| 77 (32.4) |           |
| Emphysema              | 29 (12.2) |           |
| GORD                   | 88 (37.0) |           |
| Hypertension           | 79 (33.2) |           |
| IHD                    | 52 (51.8) |           |
| Pulmonary hypertension | 13 (5.5)  |           |
| COPD                   | 10 (4.2)  |           |
| Pirfenidone            | 79 (33.2) |           |
| Nintedanib             | 7 (2.9)   |           |
| N-Acetylcystein        | 15 (6.3)  |           |
| Prednisolone           | 17 (7.1)  |           |
| Home oxygen            | 49 (20.6) |           |
| FVC (% predicted)      | 77.68 (17.34) |     |
| FEV₁ (% predicted)     | 82.18 (18.28) |     |
| DLCO (% predicted)     | 47.75 (14.97) |     |

Table 2. Descriptive statistics of variables observed over 12 months.

|                        | First visit | Second visit |
|------------------------|-------------|--------------|
|                        | N           | Mean (SD)    | N           | Mean (SD)    |
| SGRQ                   | 226         | 42.64 (19.15)| 195         | 44.64 (19.34)|
| K-BILD                 | 224         | 55.71 (14.02)| 191         | 55.59 (13.67)|
| mMRC                   | 215         | 2.71 (1.05)  | 190         | 2.72 (1.05)  |
| HADS total             | 220         | 10.68 (7.36) | 185         | 10.99 (7.38) |
| UCSD-SOBQ              | 188         | 38.29 (28.38)| 147         | 39.89 (28.02)|
| EQ-5D                  | 238         | 0.69 (0.22)  | 200         | 0.68 (0.24)  |
| SGRQ-I                 | 226         | 43.58 (22.49)| 195         | 45.50 (22.98)|
| FVC (%)                | 165         | 77.68 (7.34) | 104         | 77.67 (17.32)|
| FEV₁ (%)               | 163         | 82.18 (18.28)| 104         | 81.52 (17.20)|
| 6MWD                   | 116         | 329.66 (138.02)| 104 | 330.51 (139.32)|

SGRQ: St George’s Respiratory Questionnaire, K-BILD: King’s Brief Interstitial Lung Disease Questionnaire, mMRC: Medical Research Council dyspnea score, HADS: hospital anxiety and depression scale, UCSD-SOB: University of California, San Diego shortness of breath questionnaire, EQ-5D-5 L: EuroQol 5 Dimension 5 Level, SGRQ-I: St George’s Respiratory Questionnaire–interstitial lung disease, FEV₁: forced expiratory volume in 1 s, FVC: forced vital capacity, 6MWD: 6 min walk test distance.

0.91 (0.90, 0.92), K-BILD: 0.95 (0.94, 0.95), SGRQ: 0.94 (0.93, 0.94) and UCSD-SOBQ: 0.98 (0.97, 0.98).

Chronic Respiratory Disease
used PROMs concurrently. We have shown that all questionnaires investigated in this study had good internal consistency and high degree of correlations with other tools, consistent with good convergent validity. However, the convergent validity between FVC and 6-min walk distance and the PROMs was poor suggesting that physiological measurements only capture a small component of HRQOL or breathlessness. The SGRQ, SGRQ-I, EQ-5D, mMRC, UCSD and K-BILD were able to discriminate individuals according to accepted physiological measure of disease severity in contrast to HADS suggesting that these reflect disease severity better. K-BILD, EQ-5D, mMRC and SGRQ and SGRQ-I were associated with mortality at 1 year whereas mMRC, HADS, UCSD and FVC % predicted ≤75% were not. This suggests HRQOL is a major determinant of outcome; the multiple domains capture aspects of disease severity better than breathlessness or physiology alone. The median MCID (range) for K-BILD was 6.3 (4.1–7.0), SGRQ was 7.0 (3.8–9.6), mMRC was 0.4 (0.1–0.5), UCSD was 9.6 (4.1–14.2) and HADS was 2.4 (0.9–3.7).

### Strengths and limitations

This was a prospective longitudinal study recruiting 250 patients varying in disease severity. We used a multicentre approach and wide entry criteria to reflect real world population. As a result, comorbidities were common in our population with half of patients having at least one co-morbidity at a rate similar to the German registry. We have not considered comorbidities and change in health status may have been due to factors, such as pulmonary rehabilitation or oxygen therapy that was not captured in our study. However, including individuals with comorbidities increases the generalisability of our findings.

Participants’ outcome measures were relatively static during study period and there was only a small number of individuals showed minimal change in PGIC (n = 36). We employed both anchor- and distribution-based methods as is recommended. There was a large difference between the distribution-based MCIDs and the anchor-based MCIDs with the distribution-based methods giving significantly larger values, especially the 0.5 standard deviation (SD).

### Table 3. Convergent validity.

| Measure   | SGRQ | EQ-5D | MRC | HADS | K-BILD | UCSD | SGRQ-I | FVC % pred | 6MWD |
|-----------|------|-------|-----|------|--------|------|--------|------------|------|
| SGRQ      | 1    |       | -0.74 | 0.68 | 0.67   | -0.84 | 0.83   | 0.97       | -0.36 | -0.29   |
| EQ-5D     | 1    | -0.60 |     | -0.66 | 0.73   | -0.78 | -0.74  | 0.34       | 0.28  |
| MRC       | 1    | 0.49  |     | -0.63 | 0.74   | 0.67  | -0.35  |           | -0.38 |
| HADS      | 1    | -0.74 |     | 0.60  | 0.64   | -0.13 | -0.15  |           |       |
| K-BILD    | 1    | -0.74 |     | -0.81 | 0.33   | 0.25  |        |           |       |
| UCSD      | 1    |       |     | 0.822 | -0.28  |       | -0.34  |           | -0.29 |
| SGRQ-I    | 1    |       |     | -0.34 |        |       |        |           |       |
| FVC % pred| 1    |       |     |       |        |       |        |           |       |
| 6MWD      | 1    |       |     |       |        |       |        |           |       |

Correlation coefficients for EQ-5D: EQ-5D: EuroQol five Dimension, FVC: forced vital capacity, HADS: hospital anxiety and depression scale, K-BILD: King's Brief Interstitial Lung Disease Questionnaire, mMRC: Medical Research Council dyspnea score, SGRQ: St George's Respiratory Questionnaire, SGRQ-I, St George's Respiratory Questionnaire-Interstitial lung disease, UCSD: University of California, San Diego shortness of breath questionnaire, 6MWD: 6 min walk test distance. Correlations were considered as weak if < 0.30, moderate, 0.3-0.6 and strong >0.60.

### Table 4. Known group validity.

| Measure   | FVC > 75% (n = 89) mean (SD) | FVC ≤ 75% (n = 76) mean (SD) | Mean difference (95% CI) | p-value |
|-----------|-------------------------------|-------------------------------|--------------------------|---------|
| SGRQ      | 37.82 (18.13)                | 46.68 (18.16)                | 8.86 (3.20,14.53)        | 0.002   |
| EQ-5D     | 0.74 (0.18)                  | 0.64 (0.22)                  | -0.10 (-0.16,-0.03)      | 0.003   |
| MRC       | 2.38 (1.03)                  | 2.93 (0.87)                  | 0.55 (0.24,0.86)         | <0.001  |
| HADS      | 9.83 (7.90)                  | 11.41 (6.50)                 | 1.58 (-0.75,3.91)        | 0.18    |
| K-BILD    | 58.87 (14.31)                | 52.19 (12.21)                | -6.68 (-10.94,-2.41)     | 0.002   |
| UCSD      | 31.41 (25.07)                | 41.02 (26.28)                | 9.61 (0.81,18.42)        | 0.033   |
| SGRQ-I    | 39.16 (21.84)                | 47.37 (21.35)                | 8.21 (1.46,14.96)        | 0.017   |

A comparison between those with a forced vital capacity (FVC) greater than or equal or less than 75% predicted for EQ-5D: EQ-5D: EuroQol five Dimension, HADS: hospital anxiety and depression scale, K-BILD: King's Brief Interstitial Lung Disease Questionnaire, mMRC: Medical Research Council dyspnea score, SGRQ: St George's Respiratory Questionnaire, SGRQ-I, St George's Respiratory Questionnaire-Interstitial lung disease, UCSD-SOBQ: University of California, San Diego shortness of breath questionnaire. All questionnaires other than UCSD-SOBQ were able to distinguish between subgroups. N: number of participants.
Survival curves for patient related outcome measures. Kaplan–Meier curves for survival (1-year mortality) for (a) SGRQ: St George’s Respiratory Questionnaire, (b) EQ5D: 5-Level Euroqol 5-dimension, (c) mMRC: modified Medical Research Council dyspnoea scale, (d) HADS: Hospital Anxiety and Depression Score, (e) K-BILD: King’s Brief Interstitial Lung Disease Questionnaire and (f) UCSD-SOBQ: University of California, San Diego shortness of breath questionnaire. Individuals were divided into three equal groups according to the baseline total score of each questionnaire: better, middle and worse health status. A comparison was made between tertile groups. Solid lines represent the better health status, dashed lines represent middle health status and dotted lines represent worse health status.

|                  | Anchor-based method MCID (95% CI) | Distribution-based methods | Median |
|------------------|-----------------------------------|----------------------------|--------|
|                  |                                    | 0.5 × SD (95% CI)          | 1 × SEM (95% CI) |        |
| SGRQ             | 3.84 (−3.24, 10.94)               | 9.58 (8.9, 10.39)          | 6.96 (3.23, 3.77) | 6.96   |
| EQ-SD            | 0.06 (−0.01, 0.13)                | 0.11 (0.1, 0.12)           | 0.11   |
| mMRC             | 0.1 (−0.47, 0.26)                 | 0.53 (0.49, 0.57)          | 0.41 (0.19, 0.22) | 0.41   |
| HADS             | 0.89 (−1.18, 2.95)                | 3.68 (3.37, 4.06)          | 2.44 (1.12, 1.35) | 2.44   |
| K-BILD           | 4.1 (−0.50, 8.69)                 | 7.01 (6.23, 7.95)          | 6.25   |
| UCSD             | 9.55 (2.97, 16.14)                | 14.19 (13.1, 15.53)        | 9.55   |
| SGRQ-I           | 4.31 (−4.57, 13.18)               | 11.24 (10.57, 12.06)       | 8.88   |

Minimal clinically important difference using anchor and distribution methods for EQ-5D-5 L: EQ-5D: EuroQol five dimension, FVC: forced vital capacity, HADS: hospital anxiety and depression scale, K-BILD: King’s Brief Interstitial Lung Disease Questionnaire, mMRC: Medical Research Council dyspnea score, SGRQ: St George’s Respiratory Questionnaire, SGRQ-I, St George’s Respiratory Questionnaire–interstitial lung disease, UCSD: University of California, San Diego shortness of breath questionnaire. SD: standard deviation, SEM: standard error of mean.
However, 0.5 SD represents medium effect size, giving greater values than the minimally important difference. For the standard error measurement (SEM) approach, we used threshold of one SEM which is the traditionally used value in assessing MCID.

The main limitation of this study is that there was large amount of missing data especially for the spirometry and 6MWT as many individuals agreed to complete the questionnaires as they were mailed to their home but declined to attend hospital for physiological tests. Furthermore, many participants did not complete questionnaires at pre-specified time intervals. We could not use supplemental oxygen status or DLCO % predicted in our analysis due to small number of patients receiving oxygen and small number of DLCO measurements. Additionally, only a small proportion of deaths occurred in our study population, which were not cross-referenced to national databases. Therefore, a careful approach needs to be taken when interpreting our results, and further study on the roles of PROMs in survival prediction is required. We might have achieved a stronger correlation between the physiological measurements and questionnaire data had we limited the analysis to a relevant questionnaire domain such as the activity domain of the SGRQ. The PGIC asked about change since the preceding visit, and therefore we were only able to report the MCID over a short timescale; there would have been more people with a change over a 1-year period, but there would have been more patient withdrawals and recall basis. The correlations between the PGIC and most of the PROMs assessed were weak and less than the recommended correlation coefficient >0.3 for determining MCIDs. Future studies should consider using alternative anchors such as the Patient Global Impression of Severity scale, which assesses severity of the condition in real time, as it is not susceptible to patients having to recall their previous health states.

This study was conducted shortly after National Institute for Health and Care Excellence (NICE) approval for pirfenidone and nintedanib, therefore, few people were receiving these treatments and we did not undertake subgroup analysis with those receiving anti-fibrotic therapy. Post hoc analysis of data from the INPULSIS trials showed that nintedanib treatment resulted in a less decline in PROMs than placebo treated group. It is likely therefore that changes in PROMs will be different if patients are receiving anti-fibrotic medication.

**Comparison with existing literature**

The findings of our study are in keeping with a Danish IPF study which reported high internal consistency, good reliability and strong concurrent validity of the K-BILD and the SGRQ-I. The MCID of SGRQ reported here (4–10) was similar to that of people with COPD (7–10) and connective tissue related ILD (4–13), and the MCID of K-BILD (4–7) was similar to that of with ILD (4–7) and IPF (3–5). The Danish team analysed the MCID for improvement separately from deterioration (SGRQ-I Total [4 and 5] and K-BILD Total [5 and 3]) suggesting that people perceive improvement and deterioration differently.

Other studies have supported the use of PROM in predicting mortality in IPF. The data from IPF-PRO Registry showed that worse health status on the SGRQ total score was associated with mortality or lung transplant over 1 year with stronger relationship than FVC% predicted. The relationship between K-BILD and survival prediction in ILD has been previously explored and reported K-BILD total score of >34 was associated with longer estimated median survival (36.4 months) than K-BILD <34 (9.7 months, p = 0.02).

We did not find the UCSD-SOBQ to be associated with mortality at 1 year. However, recent study of the German registry demonstrated greater change in UCSD-SOBQ scores from baseline (20.4 ± 1.5) in patients who died (n = 113) compared with survivors (7.0 ± 29.1). The HADS showed weak correlations with physiological measurements, which is not surprising as HADS aims to measure psychological distress. However, moderate to strong correlations between HADS and PROMs were observed, suggesting association between depression and anxiety and HRQOL. Our findings are supported by previous studies of people with ILD that reported associations between depression and UCSD-SOBQ and mMRC. However, depression (defined as HADS-D ≥ 8) and anxiety (defined as HADS-A ≥ 8) were not associated with survival rate or hospital admission rate.

**Implications for future research or clinical practice**

All the questionnaires used are related but capture different aspects of the disease. In clinical setting, mMRC dyspnoea scale rather than UCSD-SOBQ could be employed to assess breathlessness given its brevity and greater relationship to other measures of disease severity. Both the K-BILD and SGRQ were appropriate tools for evaluating HRQOL. In clinical setting, K-BILD might be more appropriate given its stronger relationship to mortality and its brevity. The SGRQ-I was not superior to the SGRQ in our study. Further studies should consider examining the psychometric properties of each domain to guide researchers to select PROMs most suitable to their needs.

**Acknowledgements**

The authors thank the following investigators for recruiting participants into the study Prof. Spiteri, Dr Steve Bianchi, Prof. Ann Millar, Dr Ian Forest, Dr Helen Parfrey and Dr Michael Gibbons.

**Declaration of conflicting interests**

The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this
article: JWK has nothing to disclose. AC has nothing to disclose. SB reports payment to King’s College Hospital for use of K-BILD from Roche Pharma, Boehringer Ingelheim, and Galapagos outside the submitted work. CA received course fees and travel to attend conference/course; April 2018 (ERS ILD School, Heidelberg) and November 2019 (Leader to Leader Course) from Boehringer Ingelheim outside the submitted work. MW has nothing to disclose. AMW reports grants from InterMune during the conduct of the study.

Funding
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This was funded by an investigator-initiated grant by InterMune International Inc (now Roche Pharmaceuticals).

ORCID iDs
Jee Whang Kim https://orcid.org/0000-0002-3063-2995
Andrew M Wilson https://orcid.org/0000-0002-5514-4867

Supplemental material
Supplemental material for this article is available online.

References
1. Guenther A, Krauss E, Tello S, et al. The European IPF registry (eurlIPFreg): baseline characteristics and survival of patients with idiopathic pulmonary fibrosis. Respir Res 2018; 19: 141. DOI: 10.1186/s12931-018-0845-5.
2. Hammond M, Clark AB, Cahn AP, et al. The efficacy and mechanism evaluation of treating idiopathic pulmonary fibrosis with the addition of co-trimoxazole (EME-TIPAC); study protocol for a randomised controlled trial. Trials 2018; 19: 89. DOI: 10.1186/s13063-018-2453-6.
3. Jones PW, Quirk FH, Baveystock CM, et al. A self-complete measure of health status for chronic airflow limitation: the St. George’s Respiratory Questionnaire. Am Rev Respir Dis 1992; 145: 1321–1327. DOI: 10.1164/ajrccm/145.6.1321.
4. Patel AS, Siegert RJ, Brignall K, et al. The development and validation of the King’s Brief Interstitial Lung Disease (K-BILD) health status questionnaire. Thorax 2012; 67: 804–810. Research Support, Non-U.S. Gov’t Validation Studies. 2012/05/05. DOI: 10.1136/thoraxjnl-2012-201581.
5. Alma H, de Jong C, Jelusic D, et al. Health status instruments for patients with COPD in pulmonary rehabilitation: defining a minimal clinically important difference. NPJ Prim Care Respir Med 2016; 26: 16041. 2016/09/07. DOI: 10.1038/nppcrm.2016.41.
6. Yorke J, Jones PW, Swigris JJ, et al. Development and validity testing of an IPF-specific version of the St George’s Respiratory Questionnaire. Thorax: Multicenter Study Randomized Controlled Trial Research Support 2010; 65: 921–926. N.H.I., Extramural Research Support. Non-U.S. Govt Validation Studies. 2010/09/24. DOI: 10.1136/thx.2010.139121.
7. Eakin EG, Resnikoff PM,rewitt LM, et al. Validation of a new dyspnea measure: the UCSD shortness of breath questionnaire. Chest 1998; 113: 619–624. Research Support, Non-U.S. Gov’t Research Support, U.S. Govt, P.H.S. 1998/03/27.
8. Papiris SA, Danni ZD, Malagari K, et al. The medical research council dyspnea scale in the estimation of disease severity in idiopathic pulmonary fibrosis. Respir Med 2005; 99: 755–761. DOI: 10.1016/j.rmed.2004.10.018.
9. Herdman M, Gudex C, Lloyd A, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res 2011; 20: 1727–1736. DOI: 10.1007/s11136-011-9903-x.
10. Antoniou K, Kamekis A, Symvoulakis EK, et al. Burden of idiopathic pulmonary fibrosis on patients’ emotional well being and quality of life: a literature review. Curr Opin Pulm Med 2020; 26: 457–463. DOI: 10.1097/MCP.0000000000000703.
11. Swigris JJ, Esser D, Conoscenti CS, et al. The psychometric properties of the St George’s Respiratory Questionnaire (SGRQ) in patients with idiopathic pulmonary fibrosis: a literature review. Health Qual Life Outcomes 2014; 12: 124. DOI: 10.1186/s12955-014-0124-1.
12. Swigris JJ, Esser D, Wilson H, et al. Psychometric properties of the St George’s Respiratory Questionnaire in patients with idiopathic pulmonary fibrosis. Eur Respir J 2017; 49: 1601788. DOI: 10.1183/13993003.01788-2016.
13. Swigris JJ, Wilson H, Esser D, et al. Psychometric properties of the St George’s Respiratory Questionnaire in patients with idiopathic pulmonary fibrosis: insights from the INPULSIS trials. BMJ Open Respir Res 2018; 5: e000278. DOI: 10.1136/bmjresp-2018-000278.
14. Prior TS, Hilberg O, Shaker SB, et al. Validation of the king’s brief interstitial lung disease questionnaire in idiopathic pulmonary fibrosis. BMC Pulm Med 2019; 19: 255–2019. DOI: 10.1186/s12890-019-01018-0.
15. Prior TS, Hoyer N, Shaker SB, et al. Validation of the IPF-specific version of St. George’s Respiratory Questionnaire. Respir Res 2019; 20: 199. DOI: 10.1186/s12931-019-1169-9.
16. Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011; 183: 788–824. 2011/04/08. DOI: 10.1164/rccm.2009-040GL.
17. King TE Jr., Behr J, Brown KK, et al. BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2008; 177: 75–81. 2007/09/29. DOI: 10.1164/rccm.200705-732OC.
18. Zigmond AS and Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983; 67: 361–370.
19. Kamper S. Global rating of change scales. Aust J Physiother 2009; 55: 289. 2009/11/26. DOI: 10.1016/s0004-9514(09)70015-7.
20. Miller M. R., Hankinson J, Brusasco V, et al. Standardisation of spirometry. *Eur Respir J* 2005; 26: 319–338.

21. ATS statement: guidelines for the six-minute walk test. *Am J Respir Crit Care Med* 2002; 166: 111–117. Guideline Practice Guideline 2002/07/02. DOI: 10.1164/ajrccm.166.1.at1102.

22. Tavakol M and Dennick R. Making sense of cronbach’s alpha. *Int J Med Educ* 2011; 2: 53–55. 2011/06/27. DOI: 10.5116/ijme.4dfb.8dfd.

23. Szentes BL, Kreuter M, Bahmer T, et al. Quality of life assessment in interstitial lung diseases: a comparison of the disease-specific K-BILD with the generic EQ-5D-5L. *Respir Res* 2018; 19: 101. DOI: 10.1186/s12931-018-0808-x.

24. Ryerson CJ, Vittinghoff E, Ley B, et al. Predicting Survival Across Chronic Interstitial Lung Disease. *Chest* 2014; 145: 723–728. 2013/10/12. DOI: 10.1378/chest.13-1474.

25. Revicki D, Hays RD, Cella D, et al. Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes. *J Clin Epidemiol* 2008; 61: 102–109. DOI: 10.1016/j.jclinepi.2007.03.012.

26. Kamper SJ, Maher CG and Mackay G. Global rating of change scales: a review of strengths and weaknesses and considerations for design. *J Man Manipulative Ther* 2009; 17: 163–170. 2010/01/05. DOI: 10.1179/jmt.2009.17.3.163.

27. Kreuter M, Swigris J, Pittrow D, et al. Health related quality of life in patients with idiopathic pulmonary fibrosis in clinical practice: insights-IPF registry. *Respir Res* 2017; 18: 139. DOI: 10.1186/s12931-017-0621-y.

28. Mouelhi Y, Jouve E, Castelli C, et al. How is the minimal clinically important difference established in health-related quality of life instruments? Review of anchors and methods. *Health Qual Life Outcomes* 2020; 18: 136. DOI: 10.1186/s12955-020-01344-w.

29. Revicki DA, Cella D, Hays RD, et al. Responsiveness and minimal important differences for patient reported outcomes. *Health Qual Life Outcomes* 2006; 4: 70. DOI: 10.1186/1477-7525-4-70.

30. Kreuter M, Wuyts WA, Wijsenbeek M, et al. Health-related quality of life and symptoms in patients with IPF treated with nintedanib: analyses of patient-reported outcomes from the INPULSIS trials. *Respir Res* 2020; 21: 36. DOI: 10.1186/s12931-020-1298-1.

31. Suzuki A, Kondoh Y, Swigris JJ, et al. Performance of the St George’s Respiratory Questionnaire in patients with connective tissue disease-associated interstitial lung disease. *Respirology* 2018; 23: 851–859. DOI: 10.1111/resp.13293.

32. Sinha A, Patel AS, Siegert RJ, et al. The king’s brief interstitial lung disease (KBILD) questionnaire: an updated minimal clinically important difference. *BMJ Open Respir Res* 2019; 6: e000363. DOI: 10.1136/bmjresp-2018-000363.

33. Nolan CM, Birring SS, Maddocks M, et al. King’s brief interstitial lung disease questionnaire: responsiveness and minimum clinically important difference. *Eur Respir J* 2019; 54: 1900281. DOI: 10.1183/13993003.00281-2019.

34. Prior TS, Hoyer N, Hilberg O, et al. Responsiveness and minimal clinically important difference of SGRQ-I and K-BILD in idiopathic pulmonary fibrosis. *Respir Res* 2020; 21: 91. 2020/04/23. DOI: 10.1186/s12931-020-01359-3.

35. Case AH, Hellkamp AS, Neely ML, et al. Associations between patient-reported outcomes and death or lung transplant in IPF: data from the IPF-PRO Registry. *Ann Am Thorac Soc* 2020; 17(6): 699–705. DOI: 10.1513/AnnalsATS.201906-4370OC.

36. Sharp C, Baggott C, Birring S, et al. S20 Kbld scores have similar power to predict survival as pulmonary physiology in idiopathic pulmonary fibrosis. *Thorax* 2016; 71: 2–A14. DOI: 10.1136/thoraxjnl-2016-209333.26.

37. Ryerson CJ, Berkeley J, Carrieri-Kohlman VL, et al. Depression and functional status are strongly associated with dyspnea in interstitial lung disease. *Chest* 2011; 139: 609–616. 2010/08/07. DOI: 10.1378/chest.10-0608.

38. Holland AE, Fiore JF, Bell EC, et al. Dyspnoea and comorbidity contribute to anxiety and depression in interstitial lung disease. *Respirology* 2014; 19: 1215–1221. DOI: 10.1111/resp.12360.

39. Lee YJ, Choi SM, Lee YJ, et al. Clinical impact of depression and anxiety in patients with idiopathic pulmonary fibrosis. *PloS one* 2017; 12: e0184300. 2017/09/12. DOI: 10.1371/journal.pone.0184300.